Want to see EDIT full AI Analyst Report?
Top Page
Editas Medicine
(NASDAQ:EDIT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-23.78% Downside)
Action:Reiterated
Date:10/09/26
The score is held back primarily by weak financial performance (continued losses and large negative operating/free cash flow) despite improving revenue, positive gross margin, and a de-risked balance sheet. Technicals are neutral-to-soft with mild negative momentum and price below key intermediate moving averages. Corporate events add upside via a newly approved clinical trial start and strengthened board expertise, but valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
Improving Revenue and Gross Margin
Growing revenue alongside a positive gross margin indicates improving commercial and economic fundamentals, even before product commercialization. If this trajectory persists, it can provide a stronger base for funding research, supporting partnerships, and gradually reducing the gap between development spending and future revenue potential.
Negative Factors
Persistent Net Losses
Deep and continuing losses show that Editas has not yet converted its scientific platform into sustainable earnings. High operating spending relative to revenue can constrain investment choices and increase the importance of successful clinical development, partnerships, or future financing to support the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue and Gross Margin
Growing revenue alongside a positive gross margin indicates improving commercial and economic fundamentals, even before product commercialization. If this trajectory persists, it can provide a stronger base for funding research, supporting partnerships, and gradually reducing the gap between development spending and future revenue potential.
Read all positive factors
Editas Medicine Key Performance Indicators (KPIs)
Any
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Data provided by:
The Fly
The FlyEditas Medicine (EDIT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$368.59M
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)2.64
Revenue Growth20.83%
EPS Growth73.89%
CountryUS
Employees87
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding153,580,030
10 Day Avg. Volume1,955,829
30 Day Avg. Volume2,917,041
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)6.67
Price to Sales (P/S)4.49
P/FCF Ratio-1.10
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit9.20
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$5.67Price Target Upside72.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$25.79M
Editas Medicine Business Overview & Revenue Model
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its l...
How the Company Makes Money
Editas Medicine primarily generates revenue from (1) collaboration and partnership arrangements and (2) to the extent applicable, licensing-related payments; as a clinical-stage company, it generally does not rely on recurring product sales. Colla...
Editas Medicine Earnings Call Summary
Earnings Call Date:Aug 07, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call highlighted significant progress in both clinical trials and in vivo pipeline development. Financial stability was assured despite a higher burn rate. However, challenges such as increased expenses and regulatory issues around fertility support present hurdles. Overall, the company's advancements in gene editing and robust clinical trial outcomes provide a positive outlook.Positive Updates
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Negative Updates
Increased Burn Rate
Higher burn rate this quarter due to increased external R&D expenses, primarily related to clinical and manufacturing costs.
Read all updates
Q2-2024 Updates
Positive
Negative
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Read all positive updates
Company Guidance
During the Editas Medicine Q2 2024 earnings call, CEO Gilmore O'Neill outlined the company's strategic progress, emphasizing three main pillars: advancing reni-cel towards BLA and commercialization, building a differentiated in vivo editing pipeline, and enhancing business development with a focus on intellectual property. The RUBY trial data for sickle cell disease showed promising results, with 18 patients having follow-up periods ranging from 2.4 to 22.8 months and demonstrating robust anemia correction. The EdiTHAL trial for beta-thalassemia included data from 7 patients with 4.1 to 12.8 months follow-up. Financially, Editas reported cash, cash equivalents, and marketable securities totaling $318 million as of June 30, 2024, with a burn rate increase due to R&D expenses. They expect to fund operations into 2026. The company is also on track to establish in vivo preclinical proof of concept by year-end, with a focus on leveraging indel technology for gene upregulation, targeting rare and orphan diseases initially.Editas Medicine Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.01M | 40.52M | 32.31M | 78.12M | 19.71M | 25.54M |
| Gross Profit | 26.75M | 40.52M | -166.93M | 72.06M | 13.38M | 20.49M |
| EBITDA | -70.23M | -148.61M | -233.11M | -147.16M | -214.09M | -187.45M |
| Net Income | -73.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.50M |
Balance Sheet | ||||||
| Total Assets | 237.36M | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M |
| Cash, Cash Equivalents and Short-Term Investments | 211.65M | 146.65M | 269.91M | 323.11M | 344.27M | 499.85M |
| Total Debt | 15.51M | 76.71M | 35.03M | 48.54M | 43.95M | 26.38M |
| Total Liabilities | 132.08M | 159.25M | 207.31M | 150.06M | 153.64M | 123.84M |
| Stockholders Equity | 105.28M | 27.29M | 134.27M | 349.10M | 360.68M | 553.64M |
Cash Flow | ||||||
| Free Cash Flow | -120.55M | -165.85M | -219.11M | -136.90M | -181.47M | -171.78M |
| Operating Cash Flow | -119.86M | -165.24M | -210.28M | -132.18M | -177.35M | -163.80M |
| Investing Cash Flow | 9.89M | 138.67M | 162.15M | -3.73M | 114.07M | -54.47M |
| Financing Cash Flow | 152.03M | 40.47M | 56.03M | 118.04M | 1.28M | 282.11M |
Editas Medicine Technical Analysis
Negative
3.28
Price Trends
2.78
Negative
2.83
Negative
2.67
Negative
Market Momentum
-0.09
Positive
42.34
Neutral
35.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDIT, the sentiment is Negative. The current price of 3.28 is above the 20-day moving average (MA) of 2.57, above the 50-day MA of 2.78, and above the 200-day MA of 2.67, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 35.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EDIT.
Editas Medicine Risk Analysis
Editas Medicine disclosed 73 risk factors in its most recent earnings report. Editas Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Editas Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $368.59M | -3.21 | -196.63% | ― | 20.83% | 73.89% | |
42 Neutral | $118.77M | -2.02 | 72.64% | ― | 51.98% | 17.68% | |
42 Neutral | $51.47M | -0.89 | -1266.43% | ― | ― | 49.43% | |
41 Neutral | $1.08B | -0.06 | -91.63% | ― | ― | 69.48% | |
41 Neutral | $57.12M | -0.49 | -89.11% | ― | 10.02% | 39.66% | |
38 Underperform | $76.04M | -1.61 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
EDIT
Editas Medicine
2.40
-0.85
-26.15%
CLLS
Cellectis SA
0.98
-2.65
-73.00%
FHTX
Foghorn Therapeutics
2.00
-2.12
-51.46%
ELTX
Elicio Therapeutics
1.90
-7.80
-80.41%
VOR
Vor Biopharma
18.26
-9.87
-35.09%
CRBU
Caribou Biosciences
0.53
-1.92
-78.29%
Editas Medicine Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Editas wins approval to launch EDIT-401 Strive trial
Positive
Oct 8, 2026
On October 8, 2026, Editas Medicine said it had secured approval in Australia to begin the Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia, while a related submission is under review in New Z...
Business Operations and StrategyExecutive/Board Changes
Editas Medicine Strengthens Board With New Cardiology Director
Positive
Aug 5, 2026
On August 3, 2026, Editas Medicine director Elliott Levy, M.D., resigned from the Board as a class I director, effective August 4, 2026, with the company stating his departure did not stem from any disagreement over operations, policies or practic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.